From DCAT Value Chain Insights (VCI)
Waters Corporation has appointed Christopher J. O'Connell as its new president, chief executive officer (CEO) and member of its board of directors, effective in September 2015. Chris joins Waters from Medtronic plc. Retiring CEO, Douglas A. Berthiaume will continue in his role as chairman of Waters' board of directors. All other leadership positions within Waters will remain in place. Waters designs, manufactures, sells, and services analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis.
Over his 21 years at Medtronic, Chris O'Connell held a variety of leadership positions, most recently as president of the Restorative Therapies Group, responsible for $7 billion in revenue and more than 16,000 employees worldwide. He provided overall strategic direction and operational management of the Group’s five divisions, as well as led the integration of the Group’s activities within the overall strategy of the corporation.
Source: Waters Corporation
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription